The capacity of BACE2 to cleave super-optimal concentrations of hIAPP in vitro and modulate fibrillogenesis suggests a potential new therapeutic approach to overcoming amyloidosis associated with T2D. The gene discussed is BACE2; the disease is amyloidosis.